Related references
Note: Only part of the references are listed.The role of aldehyde oxidase in drug metabolism
Enrico Garattini et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery
David C. Pryde et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms
Gavin P. Reynolds et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: Implications for adverse metabolic effects
Karen L. Houseknecht et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone -: An in vitro study
RS Obach et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization
Z Miao et al.
DRUG METABOLISM AND DISPOSITION (2005)
Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers
JJ Miceli et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Human liver aldehyde oxidase: Inhibition by 239 drugs
RS Obach et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia
GL Stimmel et al.
CLINICAL THERAPEUTICS (2002)
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile
AW Schmidt et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver
S Kitamura et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2001)
Inter-species variation in the metabolism and inhibition of N-[(2′-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase
PC Schofield et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
